The role of Hepatitis C Virus in hepatocarcinogenesis
|
|
- Timothy Welch
- 6 years ago
- Views:
Transcription
1 The role of Hepatitis C Virus in hepatocarcinogenesis Laura Beretta Fred Hutchinson Cancer Research Center l8 Incidence and mortality of the five most common cancers worldwide, 2000 Incidence Lung Breast Colon Stomach Liver Mortality Lung Stomach Liver 1
2 Slide 2 l8 600,000 new cases per year lberetta, 3/31/2008
3 Variations in the mortality rates of HCC (the rates are reported per 100,000 persons) El-Serag and Rudolph, Gastroenterology 2007 Risk Factors for HCC Worldwide, by area, 2000 l1 20% 15% 20% 50-60% 60-70% 70% 70% 10-20% Hepatitis B Virus Hepatitis C Virus Persistent HBV or HCV infection account for over 80% of HCC cases 2
4 Slide 4 l1 the causative agents of HCC are quite well established. lberetta, 3/28/2008
5 Trends in US Cancer Mortality Rates Liver cancer has the fastest growing death rate in the US El-Serag and Rudolph, Gastroenterology 2007 Trends in the age distribution of HCC in the US El-Serag and Rudolph, Gastroenterology
6 Hepatitis C Virus-associated Hepatocellular Carcinoma Effective population of HCV Adjusted incidence rate per 100,000 Japan USA Estimated Incidence of Acute HCV Infection United States, New Infections/100, Anti-HCV test (1 st generation) licensed Decline in transfusion recipients Decline in injection drug users Year Source: Hepatology 2000;31:777-82; Hepatology 1997;26:62S-65S; CDC, unpublished data 4
7 Hepatitis C estimated prevalence WHO Region Total Population (Millions) Hepatitis C prevalence Rate % Infected Population (Millions) Africa Americas Eastern Mediterranean Europe South-East Asia Western Pacific Total
8 l3 The connection between virus and cancer l5 Natural History of HCV Infection 3%-8% / year HCV chronic infection Noncirrhotic HCV individuals: <0.1%/year Cirrhotic patients: 3%-8%/year 6
9 Slide 11 l3 it remains a challenge to provide a clear and consistent pictire of the connection between virus and cancer whether the virus plays a direct or indirect role lberetta, 3/30/2008 Slide 12 l5 regional difference lberetta, 3/31/2008
10 Association with co-factors Environmental or genetic background underlying the incidence of HCC development reported in Japanese and Western HCV cohorts Excessive alcohol consumption HBV co-infection Overweight, Diabetes, Insulin resistance Hepatic steatosis which involves an accumulation of intracytoplasmic lipid droplets l4 Indirect involvement of the virus in HCC Chronic hepatic inflammation and cirrhosis are thought to play an important role in tumor initiation : necrosis and regeneration enhance mutagenesis in host cells, the accumulation of which culminates in HCC. 7
11 Slide 14 l4 extremely rare occurence of HCC in patients with autoimmune hepatitis in whom severe inflammation in the liver persists indefinitely absence of a complete set of genetic and epigenetic aberrations required for carcinogenesis. HCV induces genome instability lberetta, 3/31/2008
12 l6 Hepatitis C Virus Enveloped, single-stranded, positive-sense RNA virus l2 Mice with transgenic expression of viral proteins (summary of 18 models) Core protein: Development of steatosis and HCC later in life Inhibition of microsomal triglyceride transfer protein activity which is essential for hepatic lipoprotein assembly and secretion Increase the concentration of monosaturated fatty acids Activation of RXR-alpha and PPAR-alpha Induction of Insulin resistance Synergy of HCV core and alcohol in inducing oxidative stress Structural proteins Core-E1-E2: Similar results E1-E2, E2, NS3-NS4A or NS5A: No major histological changes to the liver Moriya et al J Gen Virol 1997; Moriya et al Nat Med 1998; Moriya et al Cancer Res 2001; Perlemuter et al FASEB J 2002; Lerat et al Gastroenterology 2002; Tsutsumi et al Hepatology 2002; Shintani et al Gastroenterology
13 Slide 15 l2 l6 its genome consists of one large open reading frame that is initially translated into one single polyprotein and subsequently cleaved into the functional protein. lberetta, 3/28/ transgenic mouse line lberetta, 3/31/2008
14 l7 Relevance - Recent reports on HCV patients Chronic hepatitis C can result in fatty changes in the liver and hepatic steatosis is associated with increased frequency of HCC. Correlation between HCV infection and insulin resistance Involvement of the liver microsomal triglyceride transfer protein in HCV induced liver steatosis Increased core genetic variability in tumors compared to adjacent cirrhotic liver, supporting the importance of core genetic variability in hepatocellular carcinogenesis. HCV core variants isolated from liver tumor but not from adjacent non-tumor tissue interact with Smad3 and inhibit the TGF-beta pathway. Mirandola et al Gastroenterology 2006, Sobesky et al Hepatology 2007, Pavio et al Oncogene 2005 These studies strongly support a direct role for core protein in liver pathogenesis. Core may predispose subjects to HCC development through its contribution to the onset of steatosis and insulin resistance. 9
15 Slide 17 l7 l9 even if we consider the variability of morphopgical observations and the diversoity of biochemical data lberetta, 3/31/2008 these data are particularly relevant considering recent reports on HCV patients lberetta, 3/31/2008
16 Recent development of cell culture models of HCV infection and replication Protein changes upon HCV replication Petra Mannova Romain Parent Sufen Shang Neha Lohia 10
17 HCV Infection of Huh7.5 cells P1 P3 P5 P12 P19 P27 Transcriptomic Proteomic Fold Change : P1 P3 P5 P12 P19 P27 P1 P3 P5 P12 P19 P27 Activation of RXRA and PPARA 11
18 Activation of the PI3K/Akt/mTOR pathway Activation of PI3K Activation of mtor Mannova et al J Virol 2005 Mannova et al MCP 2006 N-Ras/PI3K/Akt/mTOR pathway and HCV replication Increased N-Ras levels in sub-cellular sites of HCV replication and stimulation of the PI3K-Akt-mTOR pathway by HCV contribute to the maintenance of steady-state levels of HCV replication. 12
19 PI3K/Akt Oncogenic pathway frequently activated in HCV-associated HCC Normal liver PTEN Tumor mtor S6 kinase Sahin et al Clin Cancer Res 2004 The PI3K/Akt/mTOR pathway and liver progenitor cells Liver progenitor cells may be important in carcinogenesis resulting from chronic liver diseases. These cells may function as tumor progenitors. Romain Parent 13
20 The human bipotent liver progenitor HepaRG cell line Established from the peritumoral region of an HCV-induced Edmondson grade I HCC Share several markers with the regenerative neoductules of the same area studied by IHC Share some features with liver progenitor cells HES CK19 HES CK18 M2-PK OV1 Parent et al Gastroenterology 2004 Progressively acquire a polarized hepatocytic phenotype Day 2 Day 15 B H B Day 4 Day 42 H B H 14
21 Cell cycle A Cell death Translational control plays a prominent role in the hepatocytic differentiation of HepaRG liver progenitor cells Innate Immunity B C D Lipid metabolism + Drug metabolism E F G Cell morphology Cell environment and Cell movement Parent and Beretta Genome Biology 2008 H I J Over-expression of an activated mtor mutant (ΔTOR) lacking the R (repressor) domain 15
22 Impaired hepatocytic differentiation in ΔTOR-expressing HepaRG cells Parent et al Cancer Res 2007 Reversion by rapamycin of the altered phenotype Parent et al Cancer Res
23 Loss of responsiveness to TGF-β in ΔTOR-expressing HepaRG cells Cell cycle Activated mtor specifically targets: A Cell death Innate Immunity Cell death-related network: TNF superfamily members, interferons and caspases B C D Lipid metabolism + Drug metabolism Lipid homeostasis-related network PPARA, PPARD, RXRA and RXRB E F G Cell morphology Cell environment and Cell movement H I J Parent et al Cancer Res 2007 Parent and Beretta Genome Biology
24 Nude mice transplanted with Δ TOR cells expressing Firefly Luciferase week 2 Liver specific PTEN knock-out results in HCC in mice Derek Masse Garrett Booth Horie et al J Clin Invest
25 Collection of liver tissue at 3-months intervals Wild type 6 months PTEN mutant 6 months 9 months A B C D E F Hepatomegaly and liver steatosis A Liver weight (g) Control Experimental p < p < p < B Liver weight (g) months 6 months 9 months 0 596C 597C 655C 660C 680C 595E 620E 622E 627E 636E 1054E 594C 683C 584C 962C 581E 643E 652E 650E 585E 590E 964E 982E 984E 1017E 1018E 1019E 1020E 1023E 342C 461C 486C 855C 864C 902C 341E 375E 458E 467E 480E 482E 688E 827E 828E 833E 858E 903E 907E 912E Controls PTEN -/- Controls PTEN -/- Controls PTEN -/- 3 months 6 months 9 months A Oil Red 0 Staining (pixels) months 6 months 9 months B Oil Red 0 Staining (pixels) E 620E 622E 627E 636E 1054E 581E 585E 590E 643E 650E 652E 964E 982E 984E 1017E 1018E 1019E 1020E 1023E 341E 375E 458E 467E 480E 482E 688E 827E 828E 833E 858E 903E 907E 912E 3 months 6 months 9 months 19
26 US/Histology Show Early HCC at 9 months All mice develop tumors by 12 months l10 Natural History of HCV Infection 3%-8% / year Cellular metabolic disturbances 20
27 Slide 40 l10 an increasing body of evidence suggest a direct involvement in cellular metabolic disturbance lberetta, 4/1/2008
Hepatitis C in Australia:
Hepatitis C in Australia: Epidemiology and Clinical Presentation (and a bit of virology ) A/Prof Mark Douglas Hepatitis C - Distribution Te and Jensen 2010 Clin Liver Dis Hepatitis C Epidemiology Estimated
More informationThe impact of the treatment of HCV in developing Hepatocellular Carcinoma
The impact of the treatment of HCV in developing Hepatocellular Carcinoma Paul Y Kwo, MD Professor of Medicine Medical Director, Liver Transplantation Gastroenterology/Hepatology Division Indiana University
More informationHepatitis C wi w t i h Ju J dy y W y W a y t a t t
Hepatitis C with Judy Wyatt Hepatitis C and the histopathologist Pre-2006 biopsy based treatment of moderate-severe chronic hepatitis Now biopsy for: Watchful waiting, to confirm mild disease? Cirrhosis
More informationHepatocellular Carcinoma (HCC): Burden of Disease
Hepatocellular Carcinoma (HCC): Burden of Disease Blaire E Burman, MD VM Hepatology Hepatocellular Carcinoma (HCC) Primary HCCs most often arise in the setting of chronic inflammation, liver damage, and
More informationMetabolic Syndrome and HCC. Jacob George
Metabolic Syndrome and HCC Jacob George MetS and risk of HCC and ICC All with HCC and ICC between 1993 and 2005 identified in the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. For
More informationTumor incidence varies significantly, depending on geographical location.
Hepatocellular carcinoma is the 5 th most common malignancy worldwide with male-to-female ratio 5:1 in Asia 2:1 in the United States Tumor incidence varies significantly, depending on geographical location.
More informationGlobal Reporting System for Hepatitis (GRSH) An introduction. WHO Global Hepatitis Programme
Global Reporting System for Hepatitis (GRSH) An introduction WHO Global Hepatitis Programme 2018 Objectives 1. Explain the role of the new reporting system 2. Outline the reporting required from countries
More informationMicroarray Analysis and Liver Diseases
Microarray Analysis and Liver Diseases Snorri S. Thorgeirsson M.D., Ph.D. Laboratory of Experimental Carcinogenesis Center for Cancer Research, NCI, NIH Application of Microarrays to Cancer Research Identifying
More informationAn Update HBV Treatment
An Update HBV Treatment Epidemiology Natural history Treatment Daryl T.-Y. Lau, MD, MPH Associate Professor of Medicine Director of Translational Liver Research Division of Gastroenterology BIDMC, Harvard
More informationEnd Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC
End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP-BC Introduction (https://www.srtr.org) What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC
More informationEnd Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC
End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC Introduction (https://www.srtr.org) 1 What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC
More informationSteatosi epatica ed HCV
Steatosi epatica ed HCV Malattie delle vie biliari ed Epatologia Rho, Auditorium Padri Oblati, 11 Novembre 2006 Piero L. Almasio Università di Palermo HISTOPATHOLOGY Steatosis and accelerated fibrogenesis:
More informationHepatitis C. Core slides
Hepatitis C Core slides This material was prepared by the Viral Hepatitis Prevention Board The slides (or subsets) can be reproduced for educational use only, with reference to the original source and
More informationDr David Rowbotham NHS. The Leeds Teaching Hospitals. NHS Trust
Dr David Rowbotham The Leeds Teaching Hospitals NHS Trust NHS Nurses Update June 2010 Chronic Hepatitis HBV / HCV David Rowbotham Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology
More informationMedia centre. WHO Hepatitis B. Key facts. 1 of :12 AM.
1 of 5 2013-08-02 7:12 AM Media centre Hepatitis B Share Print Fact sheet N 204 Updated July 2013 Key facts Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic
More informationHepatocellular Carcinoma (HCC)
Title Slide Hepatocellular Carcinoma (HCC) Professor Muhammad Umar MBBS, MCPS, FCPS (PAK), FACG (USA), FRCP (L), FRCP (G), ASGE-M(USA), AGAF (USA) Chair & Professor of Medicine Rawalpindi Medical College
More informationLiver Cancer: Epidemiology and Health Disparities. Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals
Liver Cancer: Epidemiology and Health Disparities Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals 1. Bosch FX, et al. Gastroenterology. 2004;127(5 suppl 1):S5-S16. 2. American Cancer
More informationNIH Consensus Conference Statement. Management of Hepatitis C. March 24-26, NIH Web site. Available at:
ABC s of Hepatitis C Treatment Today Elizabeth N. Britton, MSN, FNP-BC Hepatology Services Louisiana State University Health Sciences Center ebritt@lsuhsc.edu ANAC CONFERENCE -TUCSON NOV 2012 Hepatitis
More informationEpidemiology of HCV infection among HD pts in Iran and prevention strategies
Epidemiology of HCV infection among HD pts in Iran and prevention strategies B. Einollahi Professor of Internal Medicine/Nephrology Division Baqiyatallah University of Medical Sciences 4th International
More informationBasic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need?
Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need? Rob Goldin r.goldin@imperial.ac.uk Fatty liver disease Is there fatty
More informationClinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL
Clinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL The World Health Organisation recent initiatives on HBV infection Launching of the
More informationViral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital
Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route
More informationHepatitis B. What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013
Hepatitis B What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013 Some quick facts about Hepatitis B Worldwide: 350-400 Million are chronic infections
More informationCancers due to 5 infections correspond to 18.6% of total cancer incidence
Cancers due to 5 infections correspond to 18.6% of total cancer incidence 25% of cancers of the oral cavity 68 600 (HPV) HPV 27.9% EBV 10.3% Helicobacter pylori 37.0% Cancer of the cervix 493 000 (HPV)
More informationDetection and Characterization of Hepatocellular Carcinoma by Imaging
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:S136 S140 Detection and Characterization of Hepatocellular Carcinoma by Imaging OSAMU MATSUI Department of Imaging Diagnosis and Interventional Radiology,
More informationNASH Bench to Bedside
NASH Bench to Bedside October 2006 Anna Mae Diehl, M.D. Gastroenterology Division Duke University NonAlcoholic Fatty Liver Disease Common ~1/4-1/3 1/3 US adults Outcome highly variable Course indolent
More informationAlla ricerca del virus nascosto (quando il virus dell epatitie B si occulta )
Alla ricerca del virus nascosto (quando il virus dell epatitie B si occulta ) Giovanni Raimondo Epatologia Clinica e Biomolecolare Policlinico Universitario di Messina UI/ml pg/ml HBsAg HBeAg + anti-hbe
More informationViral hepatitis and Hepatocellular Carcinoma
Viral hepatitis and Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationNATURAL HISTORY OF HEPATITIS B
NATURAL HISTORY OF HEPATITIS B AND DIAGNOSTIC: STATE OF THE ART O. BAHRI LABORATORY OF MEDICAL BIOLOGY AZIZA OTHMANA HOSPITAL TUNIS, TUNISIA The 2 nd Congress of The Federation of Arab Societies of Clinical
More informationAutoimmune Hepatitis Events Easl
Autoimmune Hepatitis Events Easl 1 / 6 2 / 6 3 / 6 Autoimmune Hepatitis Events Easl INTRODUCTION. Autoimmune hepatitis is a chronic, inflammatory disease of the liver that is characterized by circulating
More informationHepatitis C in Disclosures
Hepatitis C in 2018 Sandeep Mukherjee, MD CHI Health and Creighton University Medical Center Division of Gastroenterology Grant support: Abbvie Disclosures Speaker: Abbvie, Gilead, Merck Section editor
More informationEnvelope e_ :------, Envelope glycoproteins e_ ~ Single-stranded RNA ----, Nucleocapsid
Virus Antib(tdies Your Expertise, Our Antibodies, Accelerated Discovery. Envelope e_---------:------, Envelope glycoproteins e_-------1~ Single-stranded RNA ----, Nucleocapsid First identified in 1989,
More informationHBV NATURAL HISTORY. Mitchell L. Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia
HBV NATURAL HISTORY AND MANAGMENT Mitchell L. Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia IVer Liver Institute of Virginia Education,
More informationHepatitis B Virus infection: virology
Hepatitis B Virus infection: virology 167 Falk Symposium: Liver under constant attack from fat to viruses III Falk Gastro-Konferenz 17.-21. September 2008 Congress Centrum Mainz Maura Dandri Department
More informationLiver Cancer Causes, Risk Factors, and Prevention
Liver Cancer Causes, Risk Factors, and Prevention Risk Factors A risk factor is anything that affects your chance of getting a disease such as cancer. Learn more about the risk factors for liver cancer.
More informationExploring a Link Between Spy1 and Hepatocellular Carcinoma Progression
University of Windsor Scholarship at UWindsor UWill Discover Undergraduate Conference UWill Discover 2016 Mar 29th, 4:00 PM - 5:00 PM Exploring a Link Between Spy1 and Hepatocellular Carcinoma Progression
More informationApoptosis in chronic hepatitis C
Apoptosis in chronic hepatitis C Dr med. Anna Parfieniuk-Kowerda Department of Infectious Diseases and Hepatology Medical University of Bialystok Poland APOPTOSIS Apoptosis - type I programmed cell death
More informationVirion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics
Hepadnaviruses Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics Hepatitis viruses A group of unrelated pathogens termed hepatitis viruses cause the vast majority
More informationBasic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need?
Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need? Rob Goldin r.goldin@imperial.ac.uk @robdgol FATTY LIVER DISEASE Brunt
More informationHEPATOCELLULAR CARCINOMA: AN OVERVIEW
HEPATOCELLULAR CARCINOMA: AN OVERVIEW John K. Olynyk Head, Department of Gastroenterology & Hepatology Fiona Stanley Fremantle Hospital Group Dean of Research, Edith Cowan University RISING MORTALITY OF
More informationEarly life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016.
Early life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016. Outline Definition NAFLD and NASH Magnitude of the problem
More informationHEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT
HEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT INTRODUCTION: Hepatocellular carcinoma (HCC): Fifth most common cancer worldwide Third most common cause of cancer mortality In Egypt: 2.3%
More informationHepatocellular Carcinoma: Can We Slow the Rising Incidence?
Hepatocellular Carcinoma: Can We Slow the Rising Incidence? K.Rajender Reddy M.D. Professor of Medicine Director of Hepatology Medical Director of Liver Transplantation University of Pennsylvania Outline
More informationFOR REVIEW. BMB Reports - Manuscript Submission. Manuscript Draft. Manuscript Number: BMB
BMB Reports - Manuscript Submission Manuscript Draft Manuscript Number: BMB-18-095 Title: Insulin Receptor Substrate 2:A Bridge between Hippo and AKT Pathways Article Type: Perspective (Invited Only) Keywords:
More informationJMSCR Volume 03 Issue 01 Page January 2015
www.jmscr.igmpublication.org Impact Factor 3.79 ISSN (e)-2347-176x Seroprevalence of HBV among HIV Patients and Blood Donors Author Dr. Vedavati B I 1, Dr. Amrutha Kumari B 2, Dr. Venkatesha D 3 Mysore
More informationWhat is Liver Cancer? About the Liver
Your liver is important and it has many functions. The top three are that it cleans your blood of toxins, gives you energy and produces bile for digestion. What is Liver Cancer? Cancer starts when cells
More informationThe Enhancement of Toxin-Induced Liver Fibrosis in Fatty Liver Disease. Ekihiro Seki, M.D.,Ph.D. University of California San Diego
The Enhancement of Toxin-Induced Liver Fibrosis in Fatty Liver Disease Ekihiro Seki, M.D.,Ph.D. University of California San Diego - A manufactured chemical. - Does not exist naturally. Carbon tetrachloride
More informationWhite Nights of Hepatology 2016
White Nights of Hepatology 2016 Saint Petersburg, 3 June 2016 Long-term treatment of Chronic hepatitis B - a key to HCC prevention Massimo Colombo Chairman Department of Liver, Kidney, Lung and Bone Marrow
More informationHepatitis C Management and Treatment
Hepatitis C Management and Treatment Kaya Süer Near East University Faculty of Medicine Infectious Diseases and Clinical Microbiology 1 Discovery of Hepatitis C Key facts Hepatitis C: the virus can cause
More informationAlcoholic hepatitis is a drug-induced disorder
Alcoholic hepatitis is a drug-induced disorder Gyongyi Szabo, MD, PhD Professor of Medicine University of Massachusetts Medical School Source: 2 Sobernation.com Clinical Progression of ALD Mortality Acute
More informationSTOP Hepatocellular Carcinoma
STOP Hepatocellular Carcinoma Laura Tenner MD MPH, Amit G. Singal MD MS, Mamta Jain MD, Barbara Turner MD, Barbara Riske MS ReACH Center and Dept of Medicine UT Health San Antonio Dept of Medicine UT Southwestern
More informationHepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University
Hepatitis B ECHO November 29, 2017 Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University Disclosures Advisory board Gilead Comments The speaker Joseph
More informationof TERT, MLL4, CCNE1, SENP5, and ROCK1 on tumor development were discussed.
Supplementary Note The potential association and implications of HBV integration at known and putative cancer genes of TERT, MLL4, CCNE1, SENP5, and ROCK1 on tumor development were discussed. Human telomerase
More informationNAFLD/NASH. Definitions. Pathology NASH. Vicki Shah PA-C, MMS Rush University Hepatology
NAFLD/NASH Vicki Shah PA-C, MMS Rush University Hepatology Definitions NAFLD Evidence of hepatic steatosis by histology (5%) or imaging No causes for secondary fat accumulation EtOH, Drugs, hereditary
More informationExpression of NS4 HCV in liver cells of HIV/HCV co-infected patients
Expression of NS4 HCV in liver cells of HIV/HCV co-infected patients Associated prof. N.V. Matsiyeuskaya, D.Sci (Med), associated prof. M.G. Zubritskiy, MD.PHD Grodno state medical university, Belarus
More informationThis is a free sample of content from The Hepatitis B and Delta Viruses. Click here for more information on how to buy the book.
Index A Acute liver failure (ALF), viral hepatitis, 7 Adalimab, hepatitis B management in immunosuppression patients, 279 Alemtuzumab, hepatitis B management in immunosuppression patients, 280 ALF. See
More informationUniversity of Groningen. Non-alcoholic fatty liver disease Sheedfar, Fareeba
University of Groningen Non-alcoholic fatty liver disease Sheedfar, Fareeba IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check
More information-HCV genome is about 9400 nucleotides long, it is ssrna and positive sense -the 10 viral proteins are first made as a large polyprotein -individual
2013: HCV Genome -HCV genome is about 9400 nucleotides long, it is ssrna and positive sense -the 10 viral proteins are first made as a large polyprotein -individual proteins are released from polyprotein
More informationThe role of cytokines in hepatocellular carcinoma
The role of cytokines in hepatocellular carcinoma Anuradha Budhu and Xin Wei Wang 1 Liver Carcinogenesis Section, Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute,
More informationPROGRAMME AT A GLANCE
PROGRAMME AT A GLANCE Hotel Hyatt Andaz Hotel Pullman Date Hall-H1 Hall-H2 Hall-P1 Hall-P2 Hall-P3 Hall-P4 Hall-P5 Hall-P6 Basic science workshop 1 Basic Science Workshop 2 Postgraduate Course - Liver
More informationHepatitis C Resistance Associated Variants (RAVs)
Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure
More informationHEPAMAP: A ROADMAP FOR HEPATOLOGY RESEARCH IN EUROPE: AN OVERVIEW FOR POLICY MAKERS
HEPAMAP: A ROADMAP FOR HEPATOLOGY RESEARCH IN EUROPE: AN OVERVIEW FOR POLICY MAKERS HEPAMAP: A Roadmap For Hepatology Research In Europe: An Overview For Policy Makers Liver diseases are extremely costly
More informationLiver Pathology in the 0bese
Liver Pathology in the 0bese Rob Goldin Centre for Pathology, Imperial College r.goldin@imperial.ac.uk Ludwig et al. Non-alcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.
More informationM30 Apoptosense ELISA. A biomarker assay for detection and screening of NASH
M30 Apoptosense ELISA A biomarker assay for detection and screening of NASH NASH A Global Disease In the Western countries, Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common liver disease, strongly
More informationSpring 2017 Health & Wellness Seminar Series. Seminar 1: April 25 th, 2017
Spring 2017 Health & Wellness Seminar Series Seminar 1: April 25 th, 2017 1 Breakthroughs in Screening & Treatment of Liver Disease: From Hepatitis C and Fatty Liver Disease to Liver Cancer Robert S. Brown,
More informationThe Changing World of Hepatitis C
The Changing World of Hepatitis C Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia St. Paul s Hospital Site Disclosures
More informationMolecular signature for management of hepatocellular carcinoma
Molecular signature for management of hepatocellular carcinoma Yujin Hoshida, MD, PhD Liver Cancer Program, Tisch Cancer Institute Division of Liver Diseases, Department of Medicine Icahn School of Medicine
More informationJose D Sollano, MD Professor of Medicine University of Santo Tomas Manila, Philippines. University of Santo Tomas
Jose D Sollano, MD Professor of Medicine Manila, Philippines International Variation in Age-Standardized Liver Cancer Incidence Rates in Both Sexes, 2008 Global Age-Standardized Liver Cancer Incidence
More informationOutline. Updates in the Clinical Management of Hepatitis B and C. Who should be screened for HBV? Chronic Hepatitis B 10/7/2018
Outline Updates in the Clinical Management of Hepatitis B and C Jennifer C. Lai, MD, MBA Transplant Hepatologist Associate Professor of Medicine In Residence University of California, San Francisco Initial
More informationVIRUSES AND CANCER Michael Lea
VIRUSES AND CANCER 2010 Michael Lea VIRAL ONCOLOGY - LECTURE OUTLINE 1. Historical Review 2. Viruses Associated with Cancer 3. RNA Tumor Viruses 4. DNA Tumor Viruses HISTORICAL REVIEW Historical Review
More informationVIRAL AND AUTOIMMUNE HEPATITIS WHAT IS HEPATITIS?
VIRAL AND AUTOIMMUNE HEPATITIS Arthur M. Magun, M.D. Clinical Professor of Medicine WHAT IS HEPATITIS? Inflammation of the liver Almost always, inflammation implies elevation in liver enzymes AST and ALT
More informationNew insights into fatty liver disease. Rob Goldin Centre for Pathology, Imperial College
New insights into fatty liver disease Rob Goldin Centre for Pathology, Imperial College r.goldin@imperial.ac.uk Prevalence of NASH Global prevalence of NAFLD is 25% with highest prevalence in the Middle
More informationUpdate on HIV-HCV Epidemiology and Natural History
Update on HIV-HCV Epidemiology and Natural History Jennifer Price, MD Assistant Clinical Professor of Medicine University of California, San Francisco Learning Objectives Upon completion of this presentation,
More informationHepatocellular carcinoma
Hepatocellular carcinoma Mary Ann Y. Huang, M.D., M.S., FAASLD Transplant hepatologist Peak Gastroenterology Associates Porter Adventist Hospital Denver, Colorado Background - Worldwide Hepatocellular
More informationCD133 induced tumorigenicity mice express TGF-beta receptor type II (TBRII) and embryonic liver fodrin (ELF) along with stem cell markers
European Review for Medical and Pharmacological Sciences 2016; 20: 2296-2301 CD133 induced tumorigenicity mice express TGF-beta receptor type II (TBRII) and embryonic liver fodrin (ELF) along with stem
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE Worldwide Causes of HCC 60% 50% 40% 54% 30% 20% 10% 31% 15% 0% Hepatitis B Hepatitis
More informationMaviret (Glecaprevir / Pibrentasvir)
Swiss Summary of the Risk Management Plan (RMP) Maviret (Glecaprevir / Pibrentasvir) 100 mg/40 mg Film-coated tablets Version 1.0 (Dec 2016) AbbVie AG 1 Disclaimer The Risk Management Plan (RMP) is a comprehensive
More information: TP6.3 g dl, Alb4.3 g dl, GOT17 IU l, GPT26 IU l,
5 Vol. 34, pp. 5 23, 2006 C IFN 0 2 : 8 4 20 63 986 990 C 993 S7 C A F2 IFN IFNa2a 9MIU 24W HCV-RNA 995 2 F HCV-RNA IFN 0 2004 5 S8 20 mm CT SPIO-MRI 6 TP6.3 g dl, Alb4.3 g dl, GOT7 IU l, GPT26 IU l, g-gtp40
More informationEpidemiology of Hepatitis B in sub-saharan Africa. 7 February 2018 Yusuke Shimakawa, MD, PhD Institut Pasteur
Epidemiology of Hepatitis B in sub-saharan Africa 7 February 2018 Yusuke Shimakawa, MD, PhD Institut Pasteur From the Big Three to the Big Four 1600000 Number of deaths/year 1400000 HAV + HEV 1200000 1000000
More informationPrevent Hepatocellular Carcinoma through Screening, Vaccination, and Treatment of Viral Hepatitis Milena Gould Suarez, MD
Prevent Hepatocellular Carcinoma through Screening, Vaccination, and Treatment of Viral Hepatitis Milena Gould Suarez, MD Hello, my name is Milena Gould Suarez, and today I will present "Prevent Hepatocellular
More informationFatty Liver- how important is it? Jeremy F.L. Cobbold MA PhD MRCP Clinical Lecturer in Hepatology Imperial College London
Fatty Liver- how important is it? Jeremy F.L. Cobbold MA PhD MRCP Clinical Lecturer in Hepatology Imperial College London Fatty liver- how important is it? Importance in terms of: Prevalence Pathogenesis
More informationHepatitis delta: often forgotten?
15 th Annual Resistance and Antiviral Therapy Meeting Dr Sarah Hughes King s College Hospital, London Thursday 29 September 2011, Royal College of Physicians, London Hepatitis delta: often forgotten? Dr
More informationHBV : Structure. HBx protein Transcription activator
Hepatitis B Virus 1 Hepatitis B Virus 2 Properties of HBV a member of the hepadnavirus group Enveloped, partially double-stranded DNA viruses, smallest DNA virus Replication involves a reverse transcriptase
More information1. Basic principles 2. 6 hallmark features 3. Abnormal cell proliferation: mechanisms 4. Carcinogens: examples. Major Principles:
Carcinogenesis 1. Basic principles 2. 6 hallmark features 3. Abnormal cell proliferation: mechanisms 4. Carcinogens: examples Carcinogenesis Major Principles: 1. Nonlethal genetic damage is central to
More informationCURRENT TREATMENT. Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia
CURRENT TREATMENT OF HBV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia CHRONIC HBV INFECTION DEMOGRAPHICS IN THE USA Estimated
More informationDiseases to Watch. Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic
Diseases to Watch Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic steatohepatitis (NASH) - Prevalence and Symptoms - Risk Factors and Potential treatments - Target identification for NASH Robert
More informationThe Alphabet Soup of Viral Hepatitis Testing
The Alphabet Soup of Viral Hepatitis Testing August 18, 2011 Patricia Slev, PhD, DABCC Medical Director, Serologic Hepatitis and Retrovirus Laboratory, ARUP Laboratories Assistant Professor of Pathology,
More informationAntiviral agents in HCV
Antiviral agents in HCV : Upcoming Therapeutic Options Su Jong Yu, M.D., Ph.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Estimated 170 Million
More informationHepatitis C Virus and Cytokine Responses
Hepatitis C Virus and Cytokine Responses Eui-Cheol Shin, M.D., Ph.D. Laboratory of Immunology & Infectious Diseases (LIID), Graduate School of Medical Science & Engineering (GSMSE), KAIST Daejeon, Korea
More informationLearning Objectives: Hepatitis Update. Primary Causes of Chronic Liver Disease in the U.S. Hepatitis Definition. Hepatitis Viruses.
Learning Objectives: Hepatitis Update ASCLS-Michigan March 31, 2016 Dr. Kathleen Hoag Upon attendance of this seminar and review of material provided, the attendees will be able to: 1. List hepatitis viruses
More informationManagement of HepatoCellular Carcinoma
9th Symposium GIC St Louis - 2010 Management of HepatoCellular Carcinoma Overview Pierre A. Clavien, MD, PhD Department of Surgery University Hospital Zurich Zurich, Switzerland Hepatocellular carcinoma
More informationMutants and HBV vaccination. Dr. Ulus Salih Akarca Ege University, Izmir, Turkey
Mutants and HBV vaccination Dr. Ulus Salih Akarca Ege University, Izmir, Turkey Geographic Distribution of Chronic HBV Infection 400 million people are carrier of HBV Leading cause of cirrhosis and HCC
More informationImproving Access to Quality Medical Care Webinar Series
Improving Access to Quality Medical Care Webinar Series Presented by The Arizona Telemedicine Program and the Southwest Telehealth Resource Center 2015 UA Board of Regents Welcome AZ, UT, CO, NM & NV FLEX
More informationCarcinogenesis. Carcinogenesis. 1. Basic principles 2. 6 hallmark features 3. Abnormal cell proliferation: mechanisms 4. Carcinogens: examples
Carcinogenesis 1. Basic principles 2. 6 hallmark features 3. Abnormal cell proliferation: mechanisms 4. Carcinogens: examples Major Principles (cont d) 4. Principle targets of genetic damage: 4 classes
More informationHarvoni: solution to HCV
Harvoni: solution to HCV PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR. CRAIG STERN, PHARMD, MBA, RPH, FASCP, FASHP, FICA, FLMI, FAMCP Hepatitis C (HCV) Inflammation of the liver,
More informationAASLD, Boston, USA, 10 th November 2014 [oral presentation]
Effects of Sustained Virological Response on the of liver transplant, hepatocellular carcinoma, death and re-infection: meta-analysis of 129 studies in 34,563 patients with Hepatitis C infection. Andrew
More informationJournal of American Science, 2012;8(4)
Diabetes Mellitus and peripheral Insulin Resistance in Egyptian Chronic HCV Patients Treated with Standard Antiviral Therapy Amal S. Bakir, Kadry M Elsaeed, Marcel W. Keddeas Faculty of Medicine, Ain Shams
More informationTenofovir disoproxil STADA 245 mg film-coated tablets , Version 1.2 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN
Tenofovir disoproxil STADA 245 mg film-coated tablets 9.3.2016, Version 1.2 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology HIV-1 infection
More informationSerum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads. Hepatology Feb 2013
Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads Hepatology Feb 2013 Hepatitis B Surface Antigen HBsAg is the glycosylated envelope
More information/Webpages/zhang/chinese-full full- program.htm
http://www.ph.ucla.edu/epi/faculty/zhang /Webpages/zhang/chinese-full full- program.htm Cancer Incidence and Mortality and Risk Factors in the World Zuo-Feng Zhang, M.D., Ph.D. Fogarty International Training
More information